Research Studies Georgia - Join Research Studies & Research Studies

Browse Locations ... United States» ... Georgia

Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

Condition: Herpes Simplex Virus
Intervention: Device: Genexpert assay
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Not yet recruiting - verified June 2013
AR08 for Treatment of ADHD in Children

Condition: ADHD
Intervention: Drug: AR08
Sponsors: Arbor Pharmaceuticals, Inc.; Arbor Pharmaceuticals, Inc.
Recruiting - verified June 2013
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

Condition: Bacterial Conjunctivitis
Interventions: Drug: Auriclosene Ophthalmic Solution; Drug: Vehicle Ophthalmic Solution
Sponsors: NovaBay Pharmaceuticals, Inc.; NovaBay Pharmaceuticals, Inc.
Not yet recruiting - verified June 2013
Omacetaxine for Consolidation and Maintenance

Condition: Acute Myelogenous Leukemia (AML)
Intervention: Drug: Omacetaxine
Sponsors: Emory University; Emory University; Teva Pharmaceuticals USA
Recruiting - verified June 2013
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: dexmecamylamine; Drug: Placebo
Sponsors: Targacept Inc.; Targacept Inc.
Recruiting - verified June 2013
Challenge Model for Assessment of Human TB Immunity

Condition: Mycobacterium Tuberculosis
Intervention: Biological: Tice® BCG
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2013
Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial

Condition: Chronic Disease
Intervention: Behavioral: Educational print materials and coaching call
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Cancer Institute (NCI); Emory University; The University of Texas Health Science Center, Houston; Washington University in St. Louis
Not yet recruiting - verified May 2013
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Condition: Open-angle Glaucoma or Ocular Hypertension
Interventions: Drug: DE-117 ophthalmic solution; Drug: latanoprost ophthalmic solution; Other: Placebo
Sponsors: Santen Inc.; Santen Inc.
Recruiting - verified June 2013
Efficacy, Safety and Dose-Response Study of Lofexidine in the Treatment of Opioid Withdrawal Followed by Open-Label Lofexidine Treatment

Conditions: Opioid Dependence; Acute Opioid Withdrawal Syndrome
Interventions: Drug: Lofexidine HCl; Drug: Lofexidine-matching sugar pill
Sponsors: US WorldMeds LLC; US WorldMeds LLC; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2013
Effective Communication for Preventing and Responding to Oncology Adverse Events

Condition: Cancer
Intervention: Other: "We Want to Know" campaign, Patient survey at 2 time points
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified June 2013
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Condition: Influenza
Interventions: Biological: Trivalent influenza vaccine virus; Biological: Placebo
Sponsors: MedImmune LLC; MedImmune LLC; AstraZeneca, PLC
Not yet recruiting - verified May 2013
A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers

Condition: Diabetes, Diabetic Foot Ulcer
Interventions: Device: MatriStem; Device: Cellular Dermal Replacement Tissue
Sponsors: ACell Inc.; ACell Inc.
Recruiting - verified May 2013
A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)

Condition: Repeated IVF Failure
Interventions: Drug: NT100; Drug: Placebo
Sponsors: Nora Therapeutics, Inc.; Nora Therapeutics, Inc.
Recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Recruiting - verified June 2013
DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy

Condition: Cervical Spondylosis With Myelopathy
Intervention:
Sponsors: Emory University; Emory University; Siemens Medical Solutions
Recruiting - verified May 2013
Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV

Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013
Pilot Study of the Safety of a Daily Ethanol Lock for Urinary Catheters in Critically Ill Children

Condition: Complication of Urinary Catheter
Intervention: Drug: Ethanol Lock
Sponsors: Children's Healthcare of Atlanta; Children's Healthcare of Atlanta
Not yet recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of a Monoclonal Antibody in Patients With Active Thyroid Eye Disease

Conditions: Thyroid Associated Ophthalmopathies; Thyroid-Associated Ophthalmopathy
Interventions: Drug: teprotumumab; Drug: Placebo
Sponsors: River Vision Development Corporation; River Vision Development Corporation
Recruiting - verified June 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial-2

Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Subjects With Type 1 Diabetes (T1DM)

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2013
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Condition: Generalized Anxiety Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified May 2013
Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia

Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified June 2013
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified June 2013
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Intervention: Drug: VX-509
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Controlling and Lowering Blood Pressure With The MOBIUSHD™

Condition: Hypertension
Intervention: Device: MobiusHD™
Sponsors: Vascular Dynamics, Inc.; Vascular Dynamics, Inc.
Recruiting - verified May 2013
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.; Pharmacyclics
Recruiting - verified June 2013
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

Condition: Smallpox
Intervention: Biological: IMVAMUNE®
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2013
Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial

Condition: Staphylococcus Aureus
Interventions: Drug: Mupirocin cream; Drug: Mupirocin ointment
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2013
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
Tofacitinib Ointment For Chronic Plaque Psoriasis

Conditions: Psoriasis Vulgaris; Psoriasis
Interventions: Drug: tofacitinib ointment 20 mg/g; Drug: tofacitinib ointment 10 mg/g; Drug: placebo ointment (vehicle); Drug: tofacitinib ointment 20 mg/g; Drug: tofacitinib ointment 10 mg/g; Drug: placebo ointment (vehicle)
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions: Atrial Fibrillation; Percutaneous Coronary Intervention
Interventions: Drug: rivaroxaban 2.5 mg; Drug: rivaroxaban 15 mg; Drug: rivaroxaban 10 mg; Drug: aspirin (ASA); Drug: vitamin K antagonist (VKA); Drug: clopidogrel; Drug: prasugrel; Drug: ticagrelor
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Bayer Pharma AG
Recruiting - verified May 2013
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Bicalutamide
Sponsors: Southwest Oncology Group; Southwest Oncology Group; Millennium Pharmaceuticals, Inc.; National Cancer Institute (NCI)
Recruiting - verified June 2013
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Condition: Heart Failure
Interventions: Drug: BAY94-8862; Drug: Placebo; Drug: Inspra (eplerenone)
Sponsors: Bayer; Bayer
Not yet recruiting - verified June 2013
Growth and Tolerance of Infants Fed Infant Formulas

Condition: Growth and Tolerance
Interventions: Other: Control Formula; Other: Experimental Formula 1; Other: Experimental Formula 2; Other: Human Milk
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified June 2013
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Placebo for Ribavirin
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics
Recruiting - verified May 2013
An Open-label Study to Evaluate the Effect of Treatment With AMG 785 or Teriparatide in Postmenopausal Women (STRUCTURE)

Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 785; Drug: Teriparatide (TPTD)
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Condition: Spasticity
Intervention: Drug: Baclofen
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Drug: Sulfonylurea (glimepiride); Drug: DPP-4 inhibitor (sitagliptin); Drug: GLP-1 receptor agonist (liraglutide); Drug: Insulin (glargine)
Sponsors: GRADE Study Group; GRADE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Becton, Dickinson and Company; Bristol-Myers Squibb; Merck; Novo Nordisk; Hoffmann-La Roche; Sanofi
Recruiting - verified May 2013
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified June 2013
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis

Condition: Giant Cell Arteritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab placebo; Drug: prednisone; Drug: prednisone placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Bortezomib; Drug: Melphalan; Drug: Prednisone
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified May 2013
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
20120230: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis

Condition: Hyperparathyroidism, Secondary
Interventions: Drug: AMG 416; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Conditions: Amyloidosis; Systemic Light-Chain Amyloidosis
Interventions: Drug: Carfilzomib; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; Onyx Pharmaceuticals; CORE Science Solutions; Criterium Inc.
Recruiting - verified June 2013
A Safety Study of SGN-CD19A for Leukemia and Lymphoma

Conditions: Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine; Biological: NYVAC-HIV-PT1 vaccine; Biological: NYVAC-HIV-PT4 vaccine; Biological: Placebo for DNA-HIV-PT123 vaccine; Biological: Placebo for NYVAC-HIV-PT1 vaccine; Biological: Placebo for NYVAC-HIV-PT4 vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Condition: Allergic Rhinitis
Interventions: Drug: BDP Nasal Aerosol; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Condition: Pandemic Avian (H5N1) Influenza
Intervention: Biological: GSK1557484A vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Other: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
Armodafinil in Reducing Cancer-Related Fatigue in Patients With Glioblastoma Multiforme

Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Fatigue
Interventions: Drug: armodafinil; Other: Placebo
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified January 2013
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Condition: Acute Kidney Injury
Interventions: Drug: ABT-719; Drug: Placebo
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773 Placebo; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; National Surgical Adjuvant Breast and Bowel Project (NSABP); German Breast Group
Recruiting - verified June 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: leucovorin; Drug: 5-fluorouracil; Drug: irinotecan; Drug: oxaliplatin; Drug: capecitabine [Xeloda]; Drug: fluoropyrimidine-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition: Dyslipidemia
Interventions: Device: AMG 145; Device: Placebo; Drug: Atorvastatin
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BAN2401 2.5 mg/kg; Drug: BAN2401 5.0 mg/kg; Drug: BAN2401 10 mg/kg; Drug: BAN2401 5.0 mg/kg; Drug: BAN2401 10 mg/kg
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified June 2013
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Condition: Bronchiectasis
Interventions: Drug: Ciprofloxacin DPI (BAYQ3939); Drug: Placebo
Sponsors: Bayer; Bayer; Novartis
Recruiting - verified May 2013
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Placebo (administered subcutaneously); Drug: Ezetimibe; Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease
Intervention: Drug: Saxagliptin
Sponsors: Duke University; Duke University
Recruiting - verified June 2013
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Condition: Diabetic Kidney Disease
Interventions: Drug: BMS-813160; Drug: Placebo matching with BMS-813160
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
A Study of RG7667 for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients

Condition: Cytomegalovirus Infections
Interventions: Drug: RG7667; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
A Randomised Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT Using 2mL Dilution in Adults With Cervical Dystonia (CD).

Condition: Cervical Dystonia
Interventions: Drug: Dysport; Drug: Placebo, Up to 2mL
Sponsors: Ipsen; Ipsen
Recruiting - verified May 2013
An Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport In Adults With Cervical Dystonia (CD)

Condition: Cervical Dystonia
Intervention: Drug: Dysport
Sponsors: Ipsen; Ipsen
Not yet recruiting - verified May 2013
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: NXN-462; Drug: Placebo
Sponsors: NeurAxon Inc.; NeurAxon Inc.
Recruiting - verified June 2013
Side Effects and Adherence Associated With Doxycycline Use Following Medical Abortion

Condition: Abortion
Intervention:
Sponsors: Gynuity Health Projects; Gynuity Health Projects
Recruiting - verified May 2013
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Condition: Asthma
Interventions: Drug: Albuterol Spiromax® 90 mcg/inhalation; Drug: Placebo Spiromax
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Condition: Malignant Rhabdoid Tumors (MRT), Neuroblastoma
Intervention: Drug: LEE011
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Conditions: Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; B-cell Lymphomas; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia
Interventions: Drug: Ublituximab; Drug: Lenalidomide
Sponsors: TG Therapeutics, Inc.; TG Therapeutics, Inc.
Recruiting - verified May 2013
Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.

Condition: CML
Intervention: Drug: AMN107
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Attain Performa(TM) Quadripolar Lead Study

Condition: Heart Failure
Intervention: Device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified June 2013
Identification of a Plasma Proteomic Signature for Lung Cancer

Conditions: Precancerous Conditions; Carcinoma
Intervention:
Sponsors: Integrated Diagnostics; Integrated Diagnostics
Recruiting - verified May 2013
MAESTRO (Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity)

Condition: Eisenmenger Syndrome
Interventions: Drug: Macitentan 10 mg, oral tablet, to be taken once daily.; Drug: Matching placebo oral tablet, to be taken once daily.
Sponsors: Actelion; Actelion
Recruiting - verified June 2013
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Conditions: Relapsed Acute Lymphoblastic Leukemia; Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified May 2013
S-ICD® System Post Approval Study

Conditions: Primary Prevention of Sudden Cardiac Arrest; Secondary Prevention of Sudden Cardiac Arrest
Intervention: Device: S-ICD System
Sponsors: Cameron Health, Inc.; Cameron Health, Inc.; Boston Scientific Corporation
Recruiting - verified May 2013
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: PD-0332991; Drug: Letrozole; Drug: Placebo; Drug: Letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: ELND005; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified June 2013
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development

Condition: Spinal Muscular Atrophy (SMA)
Intervention:
Sponsors: Ohio State University; Ohio State University; National Institute of Neurological Disorders and Stroke (NINDS); Families of SMA; Massachusetts General Hospital; University of Iowa
Recruiting - verified June 2013
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empaglifozin placebo + Linagliptin placebo; Drug: Empagliflozin + Linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
Safety and Efficacy of Bioabsorbable Drug-Eluting Sinus Implant for Chronic Sinusitis

Condition: Chronic Sinusitis
Interventions: Drug: S8 sinus implant; Drug: continued nasal steroid spray
Sponsors: Intersect ENT; Intersect ENT
Recruiting - verified June 2013
Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Interventions: Drug: Inhaled nitric oxide; Other: Placebo
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Condition: Type 2 Diabetes in Obese Subjects
Interventions: Device: EndoBarrier; Procedure: Sham Procedure
Sponsors: GI Dynamics; GI Dynamics
Recruiting - verified May 2013
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Condition: Reduction of Hypertrophic Skin Scarring
Interventions: Drug: PF-06473871; Drug: PF-06473871
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure

Conditions: Epilepsy; Pregnancy
Intervention:
Sponsors: Emory University; Emory University; The EMMES Corporation
Recruiting - verified June 2013
PK of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

Condition: Systemic Infection
Intervention: Drug: Antibiotic
Sponsors: Duke University; Phillip Brian Smith
Recruiting - verified June 2013
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified June 2013
Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Condition: Squamous Cell Non-small Cell Lung Cancer
Intervention: Drug: Nivolumab (BMS-936558)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified June 2013
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: BMS-936558; Drug: Dacarbazine; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765; Drug: Chlorambucil
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified June 2013
Barostim HOPE4HF (Hope for Heart Failure) Study

Condition: Heart Failure
Intervention: Device: Barostim Neo system
Sponsors: CVRx, Inc.; CVRx, Inc.
Recruiting - verified June 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified June 2013
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Condition: Alzheimer's Disease
Interventions: Drug: PF-05212377 (SAM-760); Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

Condition: Asthma
Interventions: Drug: QGE031; Drug: Omalizumab; Drug: Placebo to QGE031; Drug: Placebo to omalizumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified June 2013
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

Condition: Hodgkin Disease
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Belimumab Assessment of Safety in SLE

Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy; Biological: Belimumab 10 mg/kg plus standard therapy; Other: Standard therapy
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified June 2013
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Conditions: Breast Cancer; HER2-negative Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Eisai Inc.
Recruiting - verified June 2013
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

Condition: Neuropathic Pain
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Conditions: For Donors:; Related Donors Donating PBSC to a Family Member; For Recipients:; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia
Intervention: Drug: Plerixafor
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Genzyme; Sanofi
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified June 2013
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet

Condition: Analgesia
Intervention: Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Adult Attention Deficit Hyperactivity Disorder

Condition: Adult Attention Deficit Hyperactivity Disorder
Interventions: Drug: SEP-225289; Drug: SEP-225289; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified June 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified June 2013
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Conditions: Postherpetic Neuralgia; Pain
Interventions: Drug: V116517 50-mg tablets; Drug: V116517 30-mg tablets; Drug: Pregabalin capsules; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified June 2013
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 200 mg/day; Drug: Placebo
Sponsors: TauRx Therapeutics Ltd; TauRx Therapeutics Ltd
Recruiting - verified May 2013
A Phase 1 Study to Evaluate MEDI4736

Conditions: Advanced Malignant Melanoma; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer
Intervention: Drug: MEDI4736
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified June 2013
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 150 mg/day; Drug: TRx0237 250 mg/day; Drug: Placebo
Sponsors: TauRx Therapeutics Ltd; TauRx Therapeutics Ltd
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Condition: Metastatic Melanoma
Intervention: Drug: vemurafenib + HD IL-2
Sponsors: Prometheus Laboratories; Prometheus Laboratories
Recruiting - verified May 2013
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Condition: Bipolar 1 Disorder
Interventions: Drug: ELND005; Drug: Lamotrigine; Drug: Valproic acid; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified June 2013
Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC

Condition: Non-Squamous Cell Non-small Cell Lung Cancer
Interventions: Biological: BMS-936558; Drug: Docetaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Very High Risk Subjects Who Need Aortic Valve Replacement

Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls

Condition: Transplantation, Cytomegalovirus Infections
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)

Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention

Condition: Single or Multi Vessel Disease
Intervention:
Sponsors: St. Jude Medical; St. Jude Medical
Recruiting - verified May 2013
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: SAR339658; Other: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Conditions: Deep Vein Thrombosis; Venous Thrombosis
Interventions: Drug: edoxaban tosylate; Drug: enoxaparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified June 2013
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Condition: Treatment Resistant Depression
Interventions: Device: Low Frequency Magnetic Stimulation (LFMS); Device: Sham LFMS
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Mental Health (NIMH); Yale University; Mount Sinai School of Medicine; University of Texas Southwestern Medical Center; University of Alabama at Birmingham; Emory University
Recruiting - verified June 2013
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013
The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis

Condition: Acute Appendicitis
Intervention:
Sponsors: Venaxis, Inc.; Venaxis, Inc.
Recruiting - verified May 2013
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Condition: Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions: Biological: CREON; Biological: ZENPEP; Biological: ULTRESA; Biological: PANCREAZE; Biological: other non-sponsor pancreatic enzyme replacement therapy; Other: No pancreatic enzyme replacement therapy
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Aptalis Pharma; Cystic Fibrosis Foundation; Janssen Research & Development, LLC
Recruiting - verified May 2013
Afatinib Expanded Access Program

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: empagliflozin (low dose qd); Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Empagliflozin (high dose qd); Drug: empagliflozin (high dose bid); Drug: Placebo; Drug: empagliflozin (low dose bid)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

Condition: Systemic Lupus Erythematosus
Interventions: Drug: belimumab 10mg/kg; Other: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company
Recruiting - verified May 2013
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified June 2013
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Conditions: Non-Hodgkins Lymphoma; B-cell Lymphoma; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Primary Central Nervous System Lymphoma
Intervention: Drug: Ublituximab
Sponsors: TG Therapeutics, Inc.; TG Therapeutics, Inc.
Recruiting - verified June 2013
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012
Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab; Biological: 10 mg/kg TRU-016 + Rituximab
Sponsors: Emergent Product Development Seattle LLC; Emergent Product Development Seattle LLC
Recruiting - verified May 2013
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Conditions: Breast Cancer; HER-2 Positive Breast Cancer; Triple Negative Breast Cancer
Intervention: Drug: ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
Sacroiliac Joint Fusion With iFuse Implant System (SIFI)

Conditions: Degenerative Sacroiliitis; Sacroiliac Joint Disruption
Intervention:
Sponsors: SI-BONE, Inc.; SI-BONE, Inc.
Recruiting - verified June 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified May 2013
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: CB-03-01; Drug: Vehicle; Drug: CB-03-01
Sponsors: Intrepid Therapeutics, Inc.; Intrepid Therapeutics, Inc.
Recruiting - verified June 2013
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified June 2013
National Parkinson Foundation Quality Improvement Initiative

Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013
Osteonecrosis of the Jaw (ONJ) Case Registry

Condition: Osteonecrosis of the Jaw (ONJ)
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study of Ketamine in Patients With Treatment-resistant Depression

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Ketamine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Condition: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: Drug: TRx0237; Drug: Placebo
Sponsors: TauRx Therapeutics Ltd; TauRx Therapeutics Ltd
Recruiting - verified May 2013
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Condition: Narcolepsy
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: lapatinib ditosylate; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon alfa-2a (pegIFNα-2a); Drug: Ribavirin; Drug: Ribavirin; Drug: Daclatasvir; Drug: Placebo matching Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

Condition: Cytomegalovirus Infections
Intervention: Drug: Maribavir
Sponsors: ViroPharma; ViroPharma
Recruiting - verified June 2013
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Conditions: Type 2 Diabetes; Cardiovascular Disease
Interventions: Drug: TAK-875; Drug: TAK-875 Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis

Condition: Postmenopausal Women With Osteoporosis
Interventions: Drug: AMG 785; Drug: Alendronate
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

Conditions: Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Pineal Parenchymal Tumor
Interventions: Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified June 2013
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Condition: Venous Thromboembolism (VTE)
Interventions: Drug: Betrixaban; Drug: Enoxaparin
Sponsors: Portola Pharmaceuticals; Portola Pharmaceuticals
Recruiting - verified June 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis

Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 785; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Conditions: Chronic Pain; Low Back Pain; Analgesia
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Condition: Advanced Cancer
Interventions: Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified June 2013
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

Condition: Bipolar I Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Condition: Schizophrenia
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: inotuzumab ozogamicin; Drug: FLAG (fludarabine, cytarabine and G-CSF); Drug: HIDAC (high dose cytarabine); Drug: cytarabine and mitoxantrone
Sponsors: Pfizer; Pfizer; Union Chimique Belge
Recruiting - verified June 2013
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone; Drug: Placebo + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Biological: Indoximod; Biological: Sipuleucel-T; Other: Placebo
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2013
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 16 Years With Bladder Overactivity Caused By A Neurological Condition

Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine 4 mg; Drug: Fesoterodine 8 mg; Drug: Oxybutynin; Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)

Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Conditions: Neurofibromatosis Type 1; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Childhood Visual Pathway Glioma
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: UT-15C (treprostinil diethanolamine)
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified June 2013
Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: UT-15C (treprostinil diethanolamine); Drug: Placebo
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified June 2013
Pediatric Arthritis Study of Certolizumab Pegol

Condition: Juvenile Idiopathic Arthritis (JIA)
Intervention: Drug: Certolizumab Pegol (CZP)
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
Cancer Symptom Data From Multiple Treatment Centers

Conditions: Breast Cancer; Colon Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2012
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadobutrol (Gadavist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM2)

Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified June 2013
Mechanism and Repository Study for the Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Cornea Preservation Time Study

Condition: Cornea Tissue Preservation Time
Intervention: Biological: Cornea tissue transplant
Sponsors: Case Western Reserve University; Case Western Reserve University; National Eye Institute (NEI); Jaeb Center for Health Research
Recruiting - verified May 2013
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis

Condition: Adenoviral Conjunctivitis
Interventions: Drug: NVC-422 Ophthalmic Solution, 0.33%; Drug: Vehicle Ophthalmic Solution
Sponsors: NovaBay Pharmaceuticals, Inc.; NovaBay Pharmaceuticals, Inc.
Recruiting - verified June 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Condition: Hepatitis C, Chronic
Interventions: Drug: tenofovir; Drug: midazolam; Drug: BI 201335; Drug: caffeine; Drug: tolbutamide; Drug: tolbutamide; Drug: midazolam; Drug: caffeine; Drug: pegylated interferon; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 207127; Drug: ribavirin; Drug: ribavirin; Drug: ribavirin; Drug: BI 201335; Drug: BI 207127; Drug: ribavirin; Drug: pegylated interferon; Drug: caffeine; Drug: tolbutamide; Drug: BI 207127; Drug: ribavirin; Drug: midazolam; Drug: BI 201335; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified June 2013
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Condition: Metastatic Breast Cancer
Interventions: Biological: OPT-822/OPT-821; Biological: Phosphate Buffer Saline (PBS)
Sponsors: OBI Pharma, Inc; OBI Pharma, Inc
Recruiting - verified July 2012
Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified June 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified June 2013
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Childhood Hepatocellular Carcinoma; Papillary Thyroid Cancer; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Rhabdomyosarcoma; Recurrent Thyroid Cancer; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)

Condition: Acute Spinal Cord Injury
Interventions: Drug: SUN13837 injection; Drug: Placebo
Sponsors: Asubio Pharmaceuticals, Inc.; Asubio Pharmaceuticals, Inc.
Recruiting - verified June 2013
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified June 2013
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers

Conditions: Amyotrophic Lateral Sclerosis; Nervous System Diseases; Sclerosis; Motor Neuron Disease; Spinal Cord Diseases; Central Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases; ALS
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; ALS Therapy Alliance
Recruiting - verified June 2013
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin; Drug: Aztreonam
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified June 2013
Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: turoctocog alfa
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified June 2013
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BMS-241027; Drug: BMS-241027; Drug: BMS-241027; Drug: Placebo matching BMS-241027
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified June 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Tadalafil- Tablet
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified June 2013
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified June 2013
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Isolated veno-venous ultrafiltration (AQ); Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2013
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

Condition: Hepatitis C
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of Florida
Recruiting - verified June 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Efficacy, Safety, and PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Condition: Central Precocious Puberty
Intervention: Drug: Triptorelin 22.5 mg
Sponsors: Debiopharm S.A.; Debiopharm S.A.
Recruiting - verified May 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women

Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine for Male Participants Only; Biological: Placebo Vaccine for Female Participants Only
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 3mg; Drug: Ofatumumab 30mg; Drug: Ofatumumab 60mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
Sponsors: Acceleron Pharma, Inc.; Acceleron Pharma, Inc.
Recruiting - verified May 2013
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
Veliparib, Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: veliparib; Drug: carboplatin; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified June 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Condition: Thrombocytopaenia
Interventions: Drug: eltrombopag; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013
Radiation Therapy in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexual Dysfunction
Intervention: Radiation: hypofractionated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo; Drug: GDC-0941; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified June 2013
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Condition: Hepatorenal Syndrome
Interventions: Drug: 5mg Ifetroban Injection; Drug: 15mg Ifetroban Injection; Drug: 50mg Ifetroban Injection; Drug: 150mg Ifetroban Injection; Other: 5% Dextrose in Water
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified June 2013
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified June 2013
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

Condition: Colon Cleansing
Interventions: Drug: Polyethylene glycol; Drug: Oral sodium phosphate solution
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified July 2012
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2013
Veritas in Non-Bridging Ventral Hernia Repair

Condition: Hernia
Intervention:
Sponsors: Synovis Surgical Innovations; Synovis Surgical Innovations
Recruiting - verified May 2013
Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Conditions: AtrioVentricular Nodal Reentrant Tachycardia; Supraventricular Tachycardia; Heart Disease
Intervention: Device: Freezor Xtra Cryoablation Catheter
Sponsors: Medtronic Atrial Fibrillation Solutions; Medtronic Atrial Fibrillation Solutions
Recruiting - verified January 2013
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
A Study of RG1662 in Individuals With Down Syndrome

Condition: Down Syndrome
Interventions: Drug: RG1662; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Condition: Endometrial Neoplasms
Interventions: Drug: PF-05212384; Drug: PF-05212384; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2013
Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: Cariprazine; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified June 2013
Longitudinal Studies of Brain Structure and Function in MPS Disorders

Conditions: Mucopolysaccharidosis Type I; Mucopolysaccharidosis Type II; Mucopolysaccharidosis Type VI
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Rare Diseases Clinical Research Network; National Center for Advancing Translational Science (NCATS); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2013
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVENTM in Subjects With Cancer Who Also Have Impaired Renal Function

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: E7389; Drug: E7389; Drug: E7389
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified June 2013
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Conditions: Tumors; Medical Oncology; Neoplasms
Interventions: Drug: AGS-22M6E; Drug: ASG-22CE
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.; Seattle Genetics, Inc.
Recruiting - verified June 2013
Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

Condition: Infections, Pediatrics
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Drug: Cephalexin or Clindamycin or Linezolid
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Recruiting - verified June 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified May 2013
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified June 2013
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg; Drug: SOM230 LAR 10 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Conditions: Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease
Interventions: Drug: Placebo; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2013
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

Condition: Bipolar I Disorder
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified June 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Patients Treated for SCID (1968-2010)

Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified June 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified June 2013
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Condition: Coronary Artery Disease
Intervention: Drug: Flurpiridaz F18
Sponsors: Lantheus Medical Imaging; Lantheus Medical Imaging
Recruiting - verified February 2013
Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Condition: Carotid Stenosis
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Conditions: Transitional Cell Carcinoma of Bladder; Urethra Cancer; Ureter Cancer; Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified May 2013
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2013
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Immune Monitoring and Assay Development in Organ Transplant Recipients

Conditions: Organ Transplant; Immunology
Intervention:
Sponsors: Emory University; Emory University
Recruiting - verified June 2013
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2013
Dysport® Adult Lower Limb Spasticity Study

Condition: Leg Spasticity
Interventions: Drug: Botulinum type A toxin (Dysport®); Drug: Placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified May 2013
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM4)

Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Condition: Moderate Clostridium Difficile Infection
Interventions: Drug: LFF571; Drug: Vancomycin (POC)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Childhood Supratentorial Primitive Neuroectodermal Tumor; Ewing Sarcoma of Bone; Extraosseous Ewing Sarcoma; Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Peripheral Primitive Neuroectodermal Tumor of the Kidney; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Drug: ifosfamide; Drug: etoposide; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza.

Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

Condition: Cervical Spondylotic Myelopathy
Interventions: Drug: riluzole; Drug: Placebo medication
Sponsors: AOSpine North America Research Network; AOSpine North America Research Network
Recruiting - verified May 2013
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Condition: Post Operative Pain
Intervention: Drug: oxymorphone HCl
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified May 2013
Pharmacogenomic Evaluation of Antihypertensive Responses 2

Condition: Hypertension
Intervention: Drug: metoprolol or chlorthalidone
Sponsors: National Institute of General Medical Sciences (NIGMS); National Institute of General Medical Sciences (NIGMS)
Recruiting - verified May 2013
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Re-expression of ER in Triple Negative Breast Cancers

Conditions: Breast Cancer; Breast Tumors; Breast Neoplasms
Intervention: Drug: Decitabine, LHB589, Tamoxifen
Sponsors: Emory University; Emory University; Novartis; Eisai Inc.
Recruiting - verified June 2013
Natural History Study of SCID Disorders

Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)

Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)

Condition: Contrast Induced Nephropathy
Interventions: Device: CINCOR™ System; Drug: Peri-procedural hydration
Sponsors: Osprey Medical, Inc; Osprey Medical, Inc
Recruiting - verified June 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Childhood Hepatoblastoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: alisertib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: anti-vWF Nanobody; Biological: Placebo
Sponsors: Ablynx; Ablynx
Recruiting - verified June 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Condition: Smallpox
Interventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: Placebo
Sponsors: Bavarian Nordic; Bavarian Nordic
Recruiting - verified May 2013
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
Efficacy and Safety of Adalimumab in Subjects With Active Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
AMPLATZER Cardiac Plug Clinical Trial

Conditions: Atrial Fibrillation; Ischemic Stroke; Peripheral Thromboembolism
Intervention: Device: AMPLATZER Cardiac Plug
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Recruiting - verified June 2013
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: imatinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone; Drug: Sirolimus + prednisone
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified May 2013
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Conditions: Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma
Interventions: Drug: liposomal vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: cisplatin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified June 2013
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Immunogenicity of Off-Schedule Dosing of HPV Vaccine

Condition: Human Papillomavirus
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
Adolescent Fibromyalgia Study

Condition: Fibromyalgia
Interventions: Drug: placebo; Drug: pregabalin (Lyrica)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Pregabalin In Adolescent Patients With Fibromyalgia

Condition: Fibromyalgia
Intervention: Drug: pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Conditions: Recurrent Uterine Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Leiomyosarcoma
Interventions: Other: placebo; Biological: bevacizumab; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Conditions: Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Endometrial Papillary Serous Carcinoma; Localized Unresectable Adult Primary Liver Cancer; Metastatic Gastrointestinal Carcinoid Tumor; Ovarian Carcinosarcoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Papillary Serous Carcinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Adenoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Adenoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Adenoma; Pancreatic G-cell Carcinoma; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Cancer; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Regional Gastrointestinal Carcinoid Tumor; Stage IIIA Endometrial Carcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Endometrial Carcinoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Endometrial Carcinoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma; Uterine Carcinosarcoma
Interventions: Drug: temsirolimus; Biological: bevacizumab
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)

Condition: Refractory Cutaneous T-cell Lymphoma
Interventions: Drug: bexarotene; Drug: bexarotene
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.
Recruiting - verified June 2013
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MM-121 (SAR256212) + erlotinib; Drug: Erlotinib
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Conditions: Childhood Hepatoblastoma; Stage I Childhood Liver Cancer; Stage II Childhood Liver Cancer; Stage III Childhood Liver Cancer; Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery; Drug: cisplatin; Drug: fluorouracil; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: irinotecan hydrochloride; Procedure: liver transplantation; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Condition: Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Stem Cell Related Donor Safety Study

Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified May 2013
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2013
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified June 2013
Neuropsychological and Behavioral Testing in Young Patients With Cancer

Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Hand Transplantation for the Reconstruction of Below the Elbow Amputations

Conditions: Amputation; Transplantation
Intervention: Procedure: Hand transplantation
Sponsors: Emory University; Emory University
Recruiting - verified June 2013
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage 0 Chronic Lymphocytic Leukemia; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; T-cell Large Granular Lymphocyte Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Placebo; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Clindamycin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013
Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Conditions: Diabetic Type 1 With Obstructive Pulmonary Disease; Diabetic Type 2 With Obstructive Pulmonary Disease; Asthma; COPD; Type 1 Diabetes; Type 2 Diabetes; Indeterminate Obstructive Lung Disease
Interventions: Drug: Technosphere Insulin; Drug: Usual Care
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2013
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified June 2013
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified June 2013
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.

Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Multi-Center Trial to Study Acute Liver Failure in Adults

Conditions: Acute Liver Failure; Fulminant Hepatic Failure; Acute Liver Injury
Intervention:
Sponsors: University of Texas Southwestern Medical Center; William Lee; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2013
Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Advanced Gastric Cancer; Advanced/Metastatic Non-small Cell Lung Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastatic Castration-resistant Prostate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis

Condition: Lumbar Spinal Stenosis
Interventions: Device: ACADIA® Facet Replacement System; Device: Instrumented posterolateral fusion
Sponsors: Globus Medical Inc; Globus Medical Inc
Recruiting - verified June 2013
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Pineoblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Biological: filgrastim; Drug: cisplatin; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified June 2013
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide; Drug: cyclophosphamide; Drug: cisplatin; Biological: filgrastim; Drug: carboplatin; Drug: thiotepa; Drug: methotrexate; Drug: leucovorin calcium; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Fludarabine-based Conditioning for Severe Aplastic Anemia

Condition: Anemia, Aplastic
Interventions: Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified June 2013
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Conditions: Brain Tumor; Central Nervous System Tumor
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study of Late-Occurring Complications in Childhood Cancer Survivors

Conditions: Cancer Survivor; Cardiovascular Complications; Hematopoietic/Lymphoid Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections
Interventions: Drug: Current ARV medications; Drug: Current TB medications; Drug: Current hormonal contraceptive medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission

Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2013

Research Studies Georgia - Join Research Studies & Research Studies

Welcome to Paid Research Studies.